Salicylate, a Catalytic Inhibitor of Topoisomerase II, Inhibits DNA Cleavage and Is Selective for the a Isoforms

Molecular Pharmacology

Volumn 85, Issue 2, 2014, Pages 198-207

  Bau, Jason T ^a   Kang, Zhili ^a   Austin, Caroline A ^b   Kurz, Ebba U ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; SALICYLIC ACID;

ARTICLE; CATALYSIS; CELL STRAIN MCF 7; DNA CLEAVAGE; ENZYME ACTIVITY; ENZYME INHIBITION; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; HYDROLYSIS; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN DNA BINDING;

EID: 84891853409     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.088963     Document Type: Article

References (59)

1. Armitage BA (2005). Cyanine dye-DNA interactions: intercalation, groove binding, and aggregation, in DNA Binders and Related Subjects (Waring MJ and Chaires JB eds) pp 55-76
2. Springer, Berlin/Heidelberg. Austin CA and Marsh KL (1998) Eukaryotic DNA topoisomerase II beta. Bioessays 20:215-226
3. Austin CA, Marsh KL, Wasserman RA, Willmore E, Sayer PJ, Wang JC, and Fisher LM (1995) Expression, domain structure, and enzymatic properties of an active recombinant human DNA topoisomerase II beta. J Biol Chem 270:15739-15746
4. Auzanneau C, Montaudon D, Jacquet R, Puyo S, Pouységu L, Deffieux D, Elkaoukabi- Chaibi A, De Giorgi F, Ichas F, and Quideau S et al. (2012) The polyphenolic ellagitannin vescalagin acts as a preferential catalytic inhibitor of the a isoform of human DNA topoisomerase II. Mol Pharmacol 82:134-141
5. Azarova AM, Lyu YL, Lin C-P, Tsai Y-C, Lau JY-N, Wang JC, and Liu LF (2007) Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc Natl Acad Sci USA 104:11014-11019
6. Baird CL, Harkins TT, Morris SK, and Lindsley JE (1999) Topoisomerase II drives DNA transport by hydrolyzing one ATP. Proc Natl Acad Sci USA 96:13685-13690
7. Bandele OJ and Osheroff N (2007) Bioflavonoids as poisons of human topoisomerase II alpha and II beta. Biochemistry 46:6097-6108
8. Bandele OJ and Osheroff N (2009) Cleavage of plasmid DNA by eukaryotic topoisomerase II. Methods Mol Biol 582:39-47
9. Bau JT and Kurz EU (2011) Sodium salicylate is a novel catalytic inhibitor of human DNA topoisomerase II alpha. Biochem Pharmacol 81:345-354
10. Baxter J, Sen N, Martinez VL, De Carandini MEM, Schvartzman JB, Diffley JFX, and Aragón L (2011) Positive supercoiling of mitotic DNA drives decatenation by topoisomerase II in eukaryotes. Science 331:1328-1332
11. Braña MF, Cacho M, Gradillas A, de Pascual-Teresa B, and Ramos A (2001) Intercalators as anticancer drugs. Curr Pharm Des 7:1745-1780
12. Burden DA, Froelich-Ammon SJ, and Osheroff N (2001) Topoisomerase II-mediated cleavage of plasmid DNA. Methods Mol Biol 95:283-289
13. Chène P, Rudloff J, Schoepfer J, Furet P, Meier P, Qian Z, Schlaeppi J-M, Schmitz R, and Radimerski T (2009) Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue. BMC Chem Biol 9:1
14. Classen S, Olland S, and Berger JM (2003) Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187 Proc Natl Acad Sci USA 100:10629-10634
15. Cowell IG, Sondka Z, Smith K, Lee KC, Manville CM, Sidorczuk-Lesthuruge M, Rance HA, Padget K, Jackson GH, and Adachi N et al. (2012) Model for MLL translocations in therapy-related leukemia involving topoisomerase IIb-mediated DNA strand breaks and gene proximity. Proc Natl Acad Sci USA 109:8989-8994
16. Cvetkovic RS and Scott LJ (2005) Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy. Drugs 65:1005-1024
17. Deng WG, Ruan KH, Du M, Saunders MA, and Wu KK (2001) Aspirin and salicylate bind to immunoglobulin heavy chain binding protein (BiP) and inhibit its ATPase activity in human fibroblasts. FASEB J 15:2463-2470
18. Fachinetti D, Bermejo R, Cocito A, Minardi S, Katou Y, Kanoh Y, Shirahige K, Azvolinsky A, Zakian VA, and Foiani M (2010) Replication termination at eukaryotic chromosomes is mediated by Top2 and occurs at genomic loci containing pausing elements. Mol Cell 39:595-605
19. Fortune JM and Osheroff N (1998) Merbarone inhibits the catalytic activity of human topoisomerase IIalpha by blocking DNA cleavage. J Biol Chem 273:17643-17650
20. Gao H, Huang KC, Yamasaki EF, Chan KK, Chohan L, and Snapka RM (1999) XK469, a selective topoisomerase IIbeta poison. Proc Natl Acad Sci USA 96: 12168-12173
21. Germe T and Hyrien O (2005) Topoisomerase II-DNA complexes trapped by ICRF- 193 perturb chromatin structure. EMBO Rep 6:729-735
22. Germe T, Miller K, and Cooper JP (2009) A non-canonical function of topoisomerase II in disentangling dysfunctional telomeres. EMBO J 28:2803-2811
23. Graves DE (2001) Drug-DNA interactions. Methods Mol Biol 95:161-169
24. Handa M and Guidotti G (1996) Purification and cloning of a soluble ATPdiphosphohydrolase (apyrase) from potato tubers (Solanum tuberosum). Biochem Biophys Res Commun 218:916-923
25. Harkins TT, Lewis TJ, and Lindsley JE (1998) Pre-steady-state analysis of ATP hydrolysis by Saccharomyces cerevisiae DNA topoisomerase II. 2 Kinetic mechanism for the sequential hydrolysis of two ATP. Biochemistry 37:7299-7312
26. Hawley SA, Fullerton MD, Ross FA, Schertzer JD, Chevtzoff C, Walker KJ, Peggie MW, Zibrova D, Green KA, and Mustard KJ et al. (2012) The ancient drug salicylate directly activates AMP-activated protein kinase. Science 336:918-922
27. Hu C-X, Zuo Z-L, Xiong B, Ma J-G, Geng M-Y, Lin L-P, Jiang H-L, and Ding J (2006) Salvicine functions as novel topoisomerase II poison by binding to ATP pocket. Mol Pharmacol 70:1593-1601
28. Ju B-G, Lunyak VV, Perissi V, Garcia-Bassets I, Rose DW, Glass CK, and Rosenfeld MG (2006) A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription. Science 312:1798-1802
29. Ketron AC, Denny WA, Graves DE, and Osheroff N (2012) Amsacrine as a topoisomerase II poison: importance of drug-DNA interactions. Biochemistry 51: 1730-1739
30. Kingma PS, Fortune JM, and Osheroff N (2001) Topoisomerase II-catalyzed ATP hydrolysis as monitored by thin-layer chromatography. Methods Mol Biol 95:51-56
31. Kurz EU, Leader KB, Kroll DJ, Clark M, and Gieseler F (2000) Modulation of human DNA topoisomerase IIalpha function by interaction with 14-3-3epsilon. J Biol Chem 275:13948-13954
32. Larsen AK, Escargueil AE, and Skladanowski A (2003) Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther 99:167-181
33. Lassota P, Singh G, and Kramer R (1996) Mechanism of topoisomerase II inhibition by staurosporine and other protein kinase inhibitors. J Biol Chem 271:26418-26423
34. Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, Barry EV, Asselin BL, Athale U, and Clavell LA et al. (2010) Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 11:950-961
35. Luo K, Yuan J, Chen J, and Lou Z (2009) Topoisomerase IIalpha controls the decatenation checkpoint. Nat Cell Biol 11:204-210
36. Morris SK, Baird CL, and Lindsley JE (2000) Steady-state and rapid kinetic analysis of topoisomerase II trapped as the closed-clamp intermediate by ICRF-193 J Biol Chem 275:2613-2618
37. Nitiss JL (2009a) DNA topoisomerase II and its growing repertoire of biological functions. Nat Rev Cancer 9:327-337
38. Nitiss JL (2009b) Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 9:338-350
39. Osheroff N (1989) Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide. Biochemistry 28:6157-6160
40. Osheroff N and Zechiedrich EL (1987) Calcium-promoted DNA cleavage by eukaryotic topoisomerase II: trapping the covalent enzyme-DNA complex in an active form. Biochemistry 26:4303-4309
41. Peebles KA, Baker RK, Kurz EU, Schneider BJ, and Kroll DJ (2001) Catalytic inhibition of human DNA topoisomerase IIalpha by hypericin, a naphthodianthrone from St. John's wort (Hypericum perforatum). Biochem Pharmacol 62:1059-1070
42. Pommier Y (2013) Drugging topoisomerases: lessons and challenges. ACS Chem Biol 8:82-95
43. Pommier Y, Covey JM, Kerrigan D, Markovits J, and Pham R (1987) DNA unwinding and inhibition of mouse leukemia L1210 DNA topoisomerase I by intercalators. Nucleic Acids Res 15:6713-6731
44. Qin Y, Meng L, Hu C, Duan W, Zuo Z, Lin L, Zhang X, and Ding J (2007) Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain. Mol Cancer Ther 6:2429-2440
45. Robinson MJ, Corbett AH, and Osheroff N (1993) Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II. Biochemistry 32:3638-3643
46. Robinson MJ and Osheroff N (1991) Effects of antineoplastic drugs on the poststrand- passage DNA cleavage/religation equilibrium of topoisomerase II. Biochemistry 30:1807-1813
47. Roca J (2001) Filter binding assays for topoisomerase-DNA complexes. Methods Mol Biol 95:75-80
48. Roca J and Wang JC (1992) The capture of a DNA double helix by an ATP-dependent protein clamp: a key step in DNA transport by type II DNA topoisomerases. Cell 71:833-840
49. Schmidt BH, Osheroff N, and Berger JM (2012) Structure of a topoisomerase II-DNAnucleotide complex reveals a new control mechanism for ATPase activity. Nat Struct Mol Biol 19:1147-1154
50. Sørensen BS, Sinding J, Andersen AH, Alsner J, Jensen PB, and Westergaard O (1992) Mode of action of topoisomerase II-targeting agents at a specific DNA sequence: uncoupling the DNA binding, cleavage and religation events. J Mol Biol 228:778-786
51. Toyoda E, Kagaya S, Cowell IG, Kurosawa A, Kamoshita K, Nishikawa K, Iiizumi S, Koyama H, Austin CA, and Adachi N (2008) NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform. J Biol Chem 283:23711-23720
52. Tretter EM and Berger JM (2012) Mechanisms for defining supercoiling set point of DNA gyrase orthologs: I. A nonconserved acidic C-terminal tail modulates Escherichia coli gyrase activity. J Biol Chem 287:18636-18644
53. Vaughn J, Huang S, Wessel I, Sorensen TK, Hsieh T, Jensen LH, Jensen PB, Sehested M, and Nitiss JL (2005) Stability of the topoisomerase II closed clamp conformation may influence DNA-stimulated ATP hydrolysis. J Biol Chem 280:11920-11929
54. Vávrová A and Simunek T (2012) DNA topoisomerase IIb: a player in regulation of gene expression and cell differentiation. Int J Biochem Cell Biol 44:834-837
55. Vos SM, Tretter EM, Schmidt BH, and Berger JM(2011) All tangled up: how cells direct, manage and exploit topoisomerase function. Nat Rev Mol Cell Biol 12:827-841
56. Vrooman LM, Neuberg DS, Stevenson KE, Asselin BL, Athale UH, Clavell L, Cole PD, Kelly KM, Larsen EC, and Laverdière C et al. (2011) The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer 47:1373-1379
57. Warner TD and Mitchell JA (2002) Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum? Proc Natl Acad Sci USA 99:13371-13373
58. Yin MJ, Yamamoto Y, and Gaynor RB (1998) The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396:77-80
59. Zhang S, Liu X, Bawa-Khalfe T, Lu L-S, Lyu YL, Liu LF, and Yeh ETH (2012) Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 18:1639-1642.